GALEAS™ Hereditary Plus
A clinically validated NGS panel with optimized bioinformatics for analyzing germline mutations associated with hereditary cancers - including Lynch syndrome.Complete hereditary cancer analysis at your fingertips. Streamline your testing from sample to data analysis.
Between 5 and 10% of all cancers1, including those of the breast, ovary, uterus, prostate, and gastrointestinal system can be accounted for by hereditary cancers.
Genetic testing plays a crucial role in identifying individuals who have inherited variants within cancer susceptibility genes and are at increased risk of developing hereditary cancer. This information is invaluable for guiding screening, personalized treatment and preventive strategies aimed at improving the survival and outcomes for individuals.
Multi-gene next generation sequencing (NGS) panels have emerged as a widely accepted and clinically viable option for the diagnosis of hereditable cancers. However, many targeted NGS panels struggle to identify key hereditary cancer CNVs and require additional multiplex ligation dependant probe amplification (MLPA) analysis to detect them limiting their usefulness in testing.
With its complete scope, including the detection of single nucleotide variants (SNVs), insertions and deletions (indels) and a wide range of copy number variants (CNVs), GALEAS HereditaryPlus combines an innovative NGS panel with optimized bioinformatics to offer a viable option for reducing costly and time consuming MLPA and ensure unparalleled precision in hereditary cancer testing.
GALEAS Hereditary Plus
| Cancer type | Recommended genes for screening included in GALEAS HereditaryPlus |
|---|---|
| Breast | ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, TP53 |
| Colon | APC, AXIN2, BMPR1A, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, PMS2, MSH3, MUTYH, NTLH1, POLD1, POLE, PTEN, RNF43, SMAD4, STK11, TP53 |
| Renal | BAP1, FH, FLCN, MET, SDHB, VHL |
| Ovarian | ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, SKT11, TP53, RAD51C, RAD51D |
| Prostate | ATM, BRCA1, BRCA2, CHEK2, MLH1, MSH2, MSH6, PALB2 |
| Gastric/GIST | CDH1, KIT, PDGFRA, SDHC, SDHD, SDHA |
| Brain | APC, ATM, MLH1, MSH2, MSH6, PMS2, TP53 |
| Sarcoma | EXT1, EXT2, MTAP, NF1, RECQL4, SQSTM1, TP53 |
| Pediatric (Wilms Tumor) | CDKN1C, CTR9, REST, TRIM28, WT1 |
GALEAS HereditaryPlus is an innovative Next Generation Sequencing (NGS) panel that includes a meticulously curated collection of 146 genes well-established in their associations with hereditary cancer. The targeted gene list addresses not only key cancer syndromes like Lynch syndrome but also covers rarer hereditary cancer types like Phaeochromocytoma and pediatric cancers like Wilms tumor, ensuring a comprehensive understanding of the genetic landscape. The ability to target many types of cancer in one assay enables laboratories to streamline hereditary testing workflows.
GALEAS HereditaryPlus offers unparalleled variant detection in hereditary cancer analysis
The combination of careful design and state of the art bioinformatics pipelines supports the accurate detection of SNVs, indels and a wide range of CNVs without the need for additional testing with Sanger sequencing or Multiplex Ligation-dependent Probe Amplification (MLPA) analysis. This innovative NGS panel provides unparalleled precision in hereditary cancer analysis regardless of variant type or cancer type.
SNVs: Delivers reliable identification of SNVs including direct genotyping of the MSH2 c.942+3A>T variant avoiding the need for Sanger sequencing and streamlining testing workflows.
INDELs: Accurately detects both small and large indels, including those exceeding 10 base pairs.
CNVs: Reliably and robustly identifies CNVs from single exons to whole genes and mosaic copy number variation potentially eliminating the need for MLPA in hereditary cancer testing.
With GALEAS HereditaryPlus, laboratories can trust in exceptional accuracy and reliability of variant detection across a wide range of alteration types. Our commitment to innovation and precision empowers clinicians to make informed decisions and provide personalized care to individuals at risk of hereditary cancer.
| ID | Gene | HGVS coding | HGVS protein | Genomic position |
| 22 | BRCA1 | c.1175_1214del | p.Leu392fs*5 | chr17:43094317 |
| 23 | BRCA1 | c.1175_1214del | p.Leu392fs*5 | chr17:43094317 |
| 64 | MSH2 | c.942+3A>T | p.? | chr2:47414421 |
| 65 | PMS2 | c.736_741delinsTGTGTGTGAAG | p.(Pro246Cysfs*3) | chr7:5997389 |
| 66 | MLH1 | c.1946dupC | p.(Leu650Phefs*14) | chr3:37048561 |
| 67 | MSH2 | c.1213_1217dup | p.(Leu407Thrfs*7) | chr2:47429877 |
| 68 | MSH6 | c.3562_3563del | p.(Ser1188Tyrfs*5) | chr2:47805623 |
Table 2. SNV recall was shown to be 100% across a wide range of alteration types including small and large indels
Overcoming Challenges: CNVs, mosaics and pseudogenes
While many NGS panels excel at detecting SNVs and small indels, accurately identifying CNVs associated with hereditary cancer presents a significant challenge and often requires the use of ancillary tests like MLPA to detect them reliably.
GALEAS HereditaryPlus combines an expertly constructed CNV probe design with optimized bioinformatics pipelines to enable laboratories to
In a clinical study of 64 patients with orthogonal data, GALEAS HereditaryPlus delivered an analytical sensitivity of 98.3% and an analytical specificity of 99% for CNV analysis. This high level of sensitivity and specificity guarantees the identification of critical genetic alterations associated with hereditary cancer, empowering clinicians with actionable information for disease management.
Figure 1. CNV profiles detected by GALEAS HereditaryPlus. A) BRCA1 single exon duplication, B) MSH2 single exon deletion, C) PMS2 multiple exon deletion in pseudogene D) APC whole gene deletion, E) TSC2 mosaic partial gene CNV -20%, F) APC mosaic partial gene CNV- 30%.
GALEAS HereditaryPlus eliminates the need for time-consuming and costly supplementary tests providing laboratories with a consolidated and efficient testing workflow for hereditary cancer.
Cloud-based GALEAS Analysis software delivers a comprehensive variant calling pipeline.
Cutting-edge bioinformatics pipelines are included with GALEAS HereditaryPlus. Our cloud-based software solution has been specifically tailored to work seamlessly with our NGS panel and optimized for secondary calling and comes with an in-built panel of normals to deliver optimum sensitivity for CNV calling. All of this guarantees a robust and accurate analysis of germline variants critical to ensuring reliable downstream interpretation analysis and providing clinicians with reliable data to help them make informed decisions regarding personalized care and treatment strategies.
Features of GALEAS HereditaryPlus:
146 genes with known associations to hereditary cancers
Coverage of all key cancer syndromes and pediatric cancer genes,
Full coverage of the UK National genomic test directory,
100% recall for SNVs and indels in clinical samples.
Enhanced CNV calling capabilities of key cancer susceptibility loci from single exon to whole gene alterations
Cloud-based variant calling pipelines to ensure accurate calling and reliable downstream interpretation,
In-built panel of normals for optimum sensitivity in CNV calling
Identity tracking with 24 carefully selected SNPs
Seamless integration with decision support software
Why choose GALEAS HereditaryPlus?
Avoid unnecessary ancillary testing like MLPA or Sanger sequencing
Validate and run a single workflow for all hereditary cancers.
Streamline bioinformatics with GALEAS Analysis Software
Optimized for the GALEAS HereditaryPlus panel, our cloud-based bioinformatics pipelines deliver the accurate variant calling critical for reliable downstream interpretation.
| Key quality indicator | GALEAS HereditaryPlus | Company I |
|---|---|---|
| Number of Genes | 146 | 113 |
| Capture Panel size (kb) | 809 | 403 |
| MB required for mean 100x coverage | 130 MB | 116.6 MB |
| Percentage coverage >30x | 99% | 96% |
| Percentage on bait | 71.2% | 37.0% |
| Percentage on or near bait | 81% | 61.51% |
| Percent duplication | 2.0% | 8.99% |
| SNV recall | 99.7% | 98.1% |
| Indel Recall | 100% | 97.2% |
Sequencing metrics for GALEAS HereditaryPlus . Compared with another commercial alternative, GALEAS Hereditary Plus delivers 100% more content (including CNV probes) for less than 10% more sequencing.
The GALEAS HereditaryPlus workflow is simple and easy.
gDNA, FFPE DNA samples
Prepare samples
Prepare libraries and enrich
GALEAS HereditaryPlus
Sequence
Call variants
GALEAS Analysis software
Interpret and report
Interested in adding GALEAS HereditaryPlus as a test in your laboratory?
Product Resources
| Datasheet – PDF | |
| GALEAS HereditaryPlus Poster – PDF |
Product Specifications
| Parameters | Specification |
|---|---|
| Enrichment method | Hybridization and capture |
| Number of genes | 146 |
| Capture Panel size | 809 kb |
| Sequencing platform | Illumina |
| Targets | Genes associated with hereditary cancer |
| Variant types | SNVs, CNVs and INDELs |
| Input DNA requirements* | 10ng-200ng |
| Sample type | gDNA from blood or saliva |
| Multiplexing guidance for sequencing | 500K reads per sample required to achieve 100x. This equates to 0.15Gb per sample |
Ordering Information
| Product Description | Pack Size | Catalogue Number |
|---|---|---|
| GALEAS HereditaryPlus (with enzymatic fragmentation for gDNA or FFPE) |
16 samples | NGS_GAL_HCP_FR_16 |
| 96 samples | NGS_GAL_HCP_FR_96_A/B/C/D* |
* To provide flexibility in multiplexing samples, our 96-sample kits offer a choice in adapter plate:
A = Adapter plate with indexes 1-96
B = Adapter plate with indexes 97-192
C = Adapter plate with indexes 193-288
D = Adapter plate with indexes 289-384
Thank you for your interest in GALEAS HereditaryPlus